Enzo Biochem, Inc. (NYSE:ENZ), a biotechnology company specializing in
gene identification and genetic and immune regulation technologies for
diagnostic and therapeutic applications and laboratory services, today
announced that its subsidiary, Enzo Clinical Labs, Inc., has been
selected as a regional provider of medical laboratory services for
Horizon Blue Cross Blue Shield of New Jersey.
"We are pleased to have been selected as a participating provider with
one of the top regional health insurers in our service area,” said Kevin
Krenitsky, MD, President of Enzo Clinical Labs, Inc. "As we continue to
develop our strategic plan of broadening both our geographic reach as
well as our test menu, being selected by such a well-respected insurer
as Horizon will serve us well in achieving our goals.”
About Enzo Clinical Labs
Enzo Clinical Labs is a leading regional laboratory serving the greater
New York/New Jersey area, which covers more than 20 million individuals.
The laboratory offers a full menu of state-of-the-art diagnostic
procedures in areas such as chemistry, microbiology, hematology, blood
banking as well as pathology and genetic testing. Enzo Clinical Labs is
currently undergoing an expansion in the number and complexity of tests
performed in-house. Our main location in Farmingdale, NY has the
capacity to support the expanded testing and the impact from the new
contract. Enzo Labs maintains a network of more than 25 patient service
centers, a satellite laboratory in New York City, and a full-service
phlebotomy department.
About Enzo Biochem
Enzo Biochem is engaged in the research, development, manufacture and
licensing of innovative health care products and technologies based on
molecular biology and genetic engineering techniques, and in providing
diagnostic services to the medical community. Enzo’s Life Sciences
division develops, produces and markets proprietary labeling and
detection products for gene sequencing, genetic analysis and
immunological research among others. Its catalog of over 33,000
products serves the molecular biology, drug discovery and pathology
research markets. The Company's therapeutic division is in various
stages of clinical evaluation of its proprietary immune regulation
medicines for uveitis and Crohn's Disease and conducts pre-clinical
research on several candidate compounds aimed at producing new mineral
and organic bone, including technology that could provide therapy for
osteoporosis and fractures, among other applications. Enzo’s Clinical
Labs division provides routine and esoteric reference laboratory
services for physicians in the New York Metropolitan and New Jersey
areas. Underpinning the Company’s technology and operations is an
extensive intellectual property estate in which Enzo owns or licenses
over 230 patents worldwide, and has pending applications for over 200
more. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news
release may be considered "forward-looking" statements within the
meaning of Section 27A of the Securities Act of 1933, as amended and
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements include declarations regarding the intent, belief or current
expectations of the Company and its management. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that could
materially affect actual results. The Company disclaims any obligations
to update any forward-looking statement as a result of developments
occurring after the date of this press release.
